key: cord-0809809-vep0rnz1 authors: Atay, D.; Akcay, A.; Erbey, F.; Ozturk, G. title: The impact of alternative donor types on viral infections in pediatric hematopoietic stem cell transplantation date: 2018-01-03 journal: Pediatr Transplant DOI: 10.1111/petr.13109 sha: d13a1de947c163039dfc14e30dc79895f4ed6554 doc_id: 809809 cord_uid: vep0rnz1 Viral infections remain one of the most important complications following allogeneic HSCT. Few reports compare virus infection between different donor types in pediatric patients. We retrospectively analyzed viral infections and the outcome of one hundred and seventy‐one pediatric patients (median 7.38 years) who underwent allogeneic HSCT from matched related donor (MRD, n = 71), 10 of 10 HLA allele‐matched unrelated donors (MUD1; n = 29), 9 of 10 HLA allele‐matched unrelated donors (MUD2; n = 40), and haploidentical donors (n = 31). PCR screening for BK virus, adenovirus, Epstein‐Barr virus, parvovirus B19, human herpesvirus 6, and CMV were performed routinely weekly. Infections between 0‐30, 31‐100, and 101 days‐2 years were identified separately. BK virus and CMV reactivations were significantly low in MRD transplant patients (P = .046 and P < .0001, respectively), but incidences of all virus infections between MUD1, MUD2, and haplo‐HSCT were found statistically not different. The OS was found to be affected by having one or multiple virus infection (P = .04 and P = .0008). Despite antiviral prophylaxis and treatments, post‐transplant viral infections are associated with reduced overall survival. Haplo‐HSCT is comparable with MUD transplantation in the setting of viral infections. A larger study group and prospective studies are needed to confirm this observation. Age, median (range, y) 5.9 (0.4-17.6) 6 (1.8-17.9) 6.03 (0.7-18) 6.5 (0. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .84 Male We retrospectively analyzed viral infections and the outcome of one hundred and seventy-one pediatric patients (median 7.38 years) who underwent allogeneic HSCT from January 2014 to September 2016. Patients were divided into four subgroups: patients transplanted from MRD (n = 71), 10 of 10 HLA allele-MUD (MUD1; n = 29), 9 of 10 HLA allele-MUD (MUD2; n = 40), and haploidentical donors (n = 31). Patients' characteristics were summarized in Paired-sample t test was used for the comparison of dependent variables. A two-tailed P value <.05 was considered statistically significant. Kaplan-Meier method was used for survival analysis. One hundred and seventy-one pediatric patients undergoing HSCT were enrolled to study. The median duration of follow-up was 14 months (range 1-31 months). The main diagnosis, HLA disparity, donor type, conditioning regimen, the use of corticosteroids and ATG, the median CD34+ cells of the grafts, engraftment days of neutrophils, platelets, and lymphocytes, lymphocyte count at day 100 and the day lymphocyte count >1000/mm 3 , and the existence of acute and chronic GVHD according to donor type are summarized in Table 1 . were achieved about 5 to 10 days earlier in patients receiving haplo-HSCT than in patients receiving MRD or MUD HSCT, but these differences were statistically not different ( Table 1 ). The lymphocyte count at day 100 and the day when the lymphocyte count was greater than 1000/mm 3 did not significantly differ between the four groups (Table 1) . Immunophenotypic analysis reveals a progressive but slow increase in lymphocyte subset counts from day +30 through later Table 2 . Tables 4 and 5 . Overall survival was influenced with having one or multiple viral infection (P = .04 and P = .0008). TRM at day 100 was not statistically significant between four groups, but TRM at the end of follow-up was found statistically significant (P < .0001). This significance was especially prominent between MRD and MUD1/MUD2/ haplo-transplantations (P < .0001, P = .008, and P = .03). Comparison of overall survival at the end of follow-up between the four groups was associated with significantly better survival in the MRD group (log rank test, P < .0001). Viral infections due to impaired immune reconstitution remain a cause of morbidity and mortality in HSCT patients. The incidence of viral infections can be the best indicator of immune recovery. This study, with 171 pediatric patients, is the second largest study, which reports the incidence of virus infections in children following allogeneic HSCT. We found that viral infections are especially common in the first of our knowledge, our study is the only study that compared the viral incidence between haplo-HSCT and MRD/MUD HSCT. We detected the incidence of CMV reactivation in 28.2% ofMRD patients but more than 60% of haplo-and MUD1/MUD2 HSCT recipients were positive for CMV reactivation. This difference can be explained with ethnic and geographical differences in CMV seroprevalence in Turkish population. 10, 11 In our country, the seroprevalence rates in the age groups of 1-6, 7-14, and 14-49 years were detected as 82%, 92%, and 97.8%, respectively. 11 BK virus was the second most seen virus in our study. BK virus is more frequent in the presence of MUD, haplo-HSCT, cord blood transplantation, GVHD, advanced age, and persistent thrombocytopenia. [12] [13] [14] We also found BK virus frequently among the recipients of MUD1, MUD2, and haplo-HSCT than those of MRD grafts. ADV is increasingly recognized as an important pathogen in the recipients of allogeneic HSCT. 15 The reported mortality of patients with sustained high ADV DNA level in plasma is remarkably high, varying from 20% to 80% in different studies. 16, 17 In our study, 16.1% of haplo-HSCT patients, 15% of MUD2 HSCT patients, and 6.9% of MUD1 HSCT patients developed ADV infection. PTLD, which occurs in <1% of the patients after HSCT. 18 We found nine patients who showed EBV reactivation. Interestingly, we detected the lack of PTLD, as reported also by Kanakry et al 19 Prevention and treatment of viral infections in stem cell transplant recipients Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience Haploidentical SCT in children: an update and future perspectives Definitions of cytomegalovirus infection and disease in transplant recipients Haematopoietic Stem Cell Transplantation, The EBMT Handbook, 6th edn Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients Risk factors and utility of a riskbased algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation Determinants of ethnic differences in cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 1 Seroprevalence in childhood Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based crosssectional study and review of related data in Turkey Haematopoietic Stem Cell Transplantation, The EBMT Handbook, 6th edn Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with haematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia Absence of posttransplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis Parvovirus B19 infection after transplantation: a review of 98 cases Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation The impact of alternative donor types on viral infections in pediatric hematopoietic stem cell transplantation